Peter Lawson
Stock Analyst at Barclays
(1.53)
# 3,513
Out of 5,126 analysts
101
Total ratings
43.18%
Success rate
-10.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $385 → $394 | $353.92 | +11.32% | 2 | Feb 4, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.01 | +4.71% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $108.39 | -6.82% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $32.17 | +24.34% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $13.49 | +85.32% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $7.75 | -61.29% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $43.90 | -8.88% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.81 | +66.20% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.14 | +75.44% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $6.26 | +59.74% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.53 | +58.10% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $11.61 | -48.32% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $31.98 | +62.60% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $7.83 | +40.49% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $13.48 | +18.69% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $5.66 | +165.02% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $21.03 | -33.43% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.22 | +145.90% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.03 | +191.26% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.53 | +161.44% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $97.49 | -38.46% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $8.92 | +90.58% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $16.85 | +83.98% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $12.51 | +3.92% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.17 | +130.41% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $5.67 | -38.27% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $119.72 | +204.88% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $26.53 | +73.39% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $36.81 | +1,122.49% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.82 | +2,372.53% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $48.74 | -7.67% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 4, 2026
Maintains: Overweight
Price Target: $385 → $394
Current: $353.92
Upside: +11.32%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.01
Upside: +4.71%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $108.39
Upside: -6.82%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $32.17
Upside: +24.34%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $13.49
Upside: +85.32%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $7.75
Upside: -61.29%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $43.90
Upside: -8.88%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.81
Upside: +66.20%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.14
Upside: +75.44%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $6.26
Upside: +59.74%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.53
Upside: +58.10%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $11.61
Upside: -48.32%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $31.98
Upside: +62.60%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $7.83
Upside: +40.49%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $13.48
Upside: +18.69%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $5.66
Upside: +165.02%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $21.03
Upside: -33.43%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.22
Upside: +145.90%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.03
Upside: +191.26%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.53
Upside: +161.44%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $97.49
Upside: -38.46%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $8.92
Upside: +90.58%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $16.85
Upside: +83.98%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $12.51
Upside: +3.92%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.17
Upside: +130.41%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $5.67
Upside: -38.27%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $119.72
Upside: +204.88%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $26.53
Upside: +73.39%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $36.81
Upside: +1,122.49%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.82
Upside: +2,372.53%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $48.74
Upside: -7.67%